Napabucasin

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameNapabucasin
Drug Alias NameNapabucasine那帕卡辛Napabucasina那布卡辛Napabucasinum +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSignal transducer and activator of transcription 3 inhibitors
TargetsSignal transducer and activator of transcription 3
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPharmaceutics International IncBoston Biomedical Inc1globe Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBoston Biomedical IncPharmaceutics International Inc1globe Health Institute Llc +[6] 
Inactive CompaniesSumitomo Pharma America IncSumitomo Pharmaceuticals Co Ltd
Active IndicationsGastroesophageal Junction NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[8] 
Inactive IndicationsSolid tumoursHematologic NeoplasmsGastrointestinal Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksKEGG